First of all, around the progressive licensing, I interpreted it the same way that Steven did. So Health Canada might make a drug for cancer available to patients where, before, we might have required studies that showed a benefit in decreasing the risk of death with the cancer, and now it would be approved on the basis of showing a shrinkage of the tumour on an x-ray, for example.
If that's the case, then you can amalgamate all the data you want from around the world, but if you don't have the data that looks at the hard clinical outcome, you're not going to have the ultimate answer you want.
I'm sorry, what was the second part of that question?